## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Cornerstone Community Development, Winterwood, CVS Health, and Community Organizations Announce the Prichard Centennial Residential Reveal and Next-Phase Preview**
- Source: PR Newswire | 20251201T150000 | Bullish | Relevance: 99%
- Cornerstone Community Development, Winterwood, CVS Health, and other community organizations are hosting the Prichard Centennial Residential Reveal & Next-Phase Preview in Huntington, W.Va. The event celebrates the transformation of the historic Prichard building into affordable senior housing, supported by over $17 million in investment from CVS Health. This initiative highlights a commitment to revitalizing downtown Huntington, expanding housing opportunities, and improving community well-being.

**2. Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields**
- Source: Benzinga | 20251201T083000 | Somewhat-Bullish | Relevance: 99%
- This article highlights three health care stocks—CVS Health, Viatris Inc, and Bristol-Myers Squibb Co—that offer high dividend yields and have received recent analyst ratings. It details the dividend yield for each company, recent analyst actions including rating maintenances, upgrades, and price target adjustments, and their accuracy rates. The piece also includes recent news updates for each company, emphasizing their performance and strategic developments.

**3. CVS Health (NYSE: CVS) joins Prichard reveal after over $21M WV housing push**
- Source: Stock Titan | 20251201T150000 | Bullish | Relevance: 98%
- CVS Health, Cornerstone Community Development, and Winterwood are hosting a residential and next-phase preview event for the historic Prichard building in Huntington, WV. CVS Health has invested over $17 million in the Prichard adaptive-reuse project, transforming it into affordable senior housing, and more than $21 million in affordable housing across West Virginia. The event will showcase newly completed residential spaces and highlight ongoing efforts to revitalize the landmark, expand housing opportunities, and improve community well-being.

**4. CVS Health Corporation $CVS Shares Sold by Patient Capital Management LLC**
- Source: MarketBeat | 20251129T131605 | Somewhat-Bullish | Relevance: 98%
- Patient Capital Management LLC reduced its stake in CVS Health Corporation by 6.3% in the second quarter, selling 83,714 shares. Despite this, CVS remains a significant holding for the firm, while other institutional investors like Vanguard Group Inc. increased their positions. The company reported strong quarterly earnings, beat revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $89.41.

**5. American Century Companies Inc. Sells 225,537 Shares of CVS Health Corporation $CVS**
- Source: MarketBeat | 20251201T081749 | Neutral | Relevance: 97%
- American Century Companies Inc. reduced its stake in CVS Health Corporation by 35.8% in Q2, selling 225,537 shares, valuing its remaining holdings at approximately $27.94 million. Despite the sell-off, institutional investors collectively own 80.66% of CVS Health. The company reported strong Q3 earnings, exceeding analyst expectations, and declared a quarterly dividend of $0.665.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 8, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |
| 2025-12-10 | UBS | $97 | $96 | +1% |
| 2025-12-10 | Barclays | $93 | $87 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-12-10 | UBS | main | Buy |
| 2025-12-10 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 8 raises (avg +6%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.67 indicates undervaluation relative to growth. Analyst sentiment positive (8 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $100.2B |
| Beta | 0.48 |
| 52W Range | $43.56 - $85.15 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.67 |
| Forward P/E | 11.0 |
| Current P/E | 11.9 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.1% (minimal 5-day change). Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.09% (CS: 42) | Neutral |
| RSI_14 | 52.0 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.006x | Above |
| vs SMA200 | 1.139x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.10
- **Stop Loss:** $75.46 (4.6% risk)
- **Target:** $82.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 206
- **Position Value:** $16,294.60
- **Portfolio %:** 16.29%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*